PTAB Nixes 6 Jazz Pharma Patents In AIA Reviews By Rivals
The Patent Trial and Appeal Board handed generic drug makers a big win on Wednesday, when it ruled six patents related to Jazz Pharmaceuticals Inc.'s narcolepsy drug Xyrem were invalid because...To view the full article, register now.
Already a subscriber? Click here to view full article